Compare BANF & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANF | RLAY |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | 2260 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.1B |
| IPO Year | N/A | 2020 |
| Metric | BANF | RLAY |
|---|---|---|
| Price | $116.73 | $18.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $124.00 | $19.50 |
| AVG Volume (30 Days) | 127.1K | ★ 2.9M |
| Earning Date | 04-16-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $6.10 | N/A |
| Revenue Next Year | $3.92 | $324.03 |
| P/E Ratio | $16.38 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $101.48 | $3.03 |
| 52 Week High | $138.15 | $20.79 |
| Indicator | BANF | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 53.95 |
| Support Level | $110.33 | $18.33 |
| Resistance Level | $121.71 | $20.59 |
| Average True Range (ATR) | 2.43 | 1.16 |
| MACD | -0.02 | -0.27 |
| Stochastic Oscillator | 52.33 | 23.72 |
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Its Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.